Table 2.
Trials identified included in the qualitative analysis
| Study, year | Setting | No of pts | Tumor histotype | ECT protocol |
|---|---|---|---|---|
| Rotunno, 201537 | Two-center, Italy | 55 | non-melanoma SC | ESOPE |
| Cabula, 201538 | Multi-center, Italy | 125 | BC | ESOPE |
| Mozzillo, 201539 | Single-center, Italy | 15 | melanoma | ESOPE |
| Landstrom, 201540 | Single-center, Sweden | 19 | HNSCC | Othera |
| Granata, 201541 | Single-center, Italy | 13 | pancreatic cancer | ESOPE |
| Kreuter, 201542 | Multi-center, Germany | 56 | various | ESOPE |
| Quaglino, 201543 | Multi-center, Europe | 121 | various | ESOPE |
| Mir-Bonafé, 201544 | Single-center, Spain | 31 | melanoma | ESOPE |
| Campana, 201445 | Single-center, Italy | 39 | HNSCC | ESOPE |
| Ricotti, 201446 | Single-center, Italy | 30 | melanoma | ESOPE |
| Campana, 201447 | Single-center, Italy | 55 | BC | ESOPE |
| Edhemovic, 201429 | Single-center, Slovenia | 16 | CRC-liver mts | ESOPEb |
| Seccia, 201448 | Single-center, Italy | 9 | HNSCC | ESOPE |
| Campana, 201450 | Two-center, Italy | 34 | STS | ESOPE |
| Solari, 201451 | Single-center, Italy | 39 | various | ESOPE |
| Di Monta, 201452 | Single-center, Italy | 19 | KS | ESOPE |
| Caracò, 201349 | Single-center, Italy | 60 | melanoma | ESOPE |
| Perrone, 201353 | Single-center, Italy | 9 | V-SCC | ESOPE |
| Benevento, 201254 | Single-center, Italy | 12 | BC | ESOPE |
| Mevio, 201255 | Single-center, Italy | 15 | HNSCC | ESOPE |
| Campana, 201220 | Single-center, Italy | 35 | BC | ESOPE |
| Latini, 201256 | Single-center, Italy | 18 | KS | ESOPE |
| Matthiessen, 201257 | Single-center, Denmark | 12 | BC | ESOPE |
| Gargiulo, 201258 | Single-center, Italy | 52 | non-melanoma SC | ESOPE |
| Campana, 201221 | Single-center, Italy | 85 | melanoma | ESOPE |
| Curatolo, 201259 | Two-center, Italy | 23 | KS | ESOPE |
| Kis, 201160 | Single-center, Hungary | 9 | melanoma | ESOPE |
| Matthiessen, 201122 | Two-center, Denmark-UK | 52 | various | ESOPE |
| Skarlatos I, 201161 | Multi-center, Greece | 52 | various | ESOPE |
| Campana, 200962 | Single-center, Italy | 52 | various | ESOPE |
| Quaglino, 200863 | Single-center, Italy | 14 | melanoma | ESOPE |
| Larkin, 200764 | Single-center, Ireland | 30 | various | ESOPE |
| Gaudy, 200665 | Single-center, France | 12 | melanoma | Otherc |
Intratumoral BLM injection (1000 IU/cm3 and tumor electroporation by means of six 1100 V/cm square wave pulses with 0.1 ms duration
In this trial, the ESOPE protocol was integrated by the application of variable geometry electrodes for the treatment of deep visceral metastases.
Intratumoral BLM injection (concentration, 4 mg/mL; dose, 1 mg/cm3 of tumor volume was followed, after 10 minutes, by the application of electric pulses (six 100 μsec-long pulses, 4 pulses/sec, electric field >600V/cm
BC = breast cancer; ECT = electrochemotherapy; CRC-liver mts = colorectal cancer liver metastases; HNSCC = head and neck squamous cell cancer; KS = Kaposi’s sarcoma; SC = skin cancer; STS = soft tissue sarcomas; V-SCC = vaginal squamous cell cancer